← Back
NeuroTrials.ai
Neurology Clinical Trial Database

IHAST

Intraoperative Hypothermia for Aneurysm Surgery Trial

Year of Publication: 2005

Authors: Michael M. Todd, Bradley J. Hindman, William R. Clarke, ..., for the Intraoperative Hypothermia for Aneurysm Surgery Trial (IHAST) Investigators

Journal: New England Journal of Medicine

Citation: N Engl J Med 2005;352:135-45

PDF: https://www.nejm.org/doi/pdf/10.1056/NEJMoa040975


Clinical Question

Does the use of intraoperative hypothermia (target temperature 33°C) during open craniotomy result in better outcomes at 90 days after surgery compared to normothermia (target temperature 36.5°C) among patients with acute aneurysmal subarachnoid hemorrhage?

Bottom Line

Intraoperative hypothermia (33°C) did not improve neurologic outcomes after craniotomy among good-grade patients (WFNS I, II, or III) with aneurysmal subarachnoid hemorrhage. At 90-day follow-up, there were no significant differences between hypothermia and normothermia groups in rates of good outcome (66% vs 63%, OR 1.14, 95% CI 0.88-1.48, p=0.32), death (6% in both groups), ICU length of stay, or total hospitalization duration. Postoperative bacteremia was more common in the hypothermia group (5% vs 3%, p=0.05). The trial's 95% confidence intervals rule out the clinically meaningful 10% absolute improvement in good outcomes that the study was designed to detect.

Major Points

  • Multicenter prospective randomized partially blinded trial at 30 centers comparing intraoperative hypothermia vs normothermia
  • 1001 patients randomized from February 2000 to April 2003; 1000 patients with follow-up data
  • Patients had good-grade SAH (WFNS I, II, or III) and underwent surgery within 14 days of hemorrhage
  • Target temperature 33°C (range 32.5-33.5°C) in hypothermia group vs 36.5°C (range 36-37°C) in normothermia group
  • Surface cooling methods used (forced-air blanket, optional circulating water mattress, optional IV cold saline)
  • Cooling initiated after intubation and positioning, before likely time of surgical injury
  • Rewarming began after final aneurysm clip secured
  • Primary outcome: Glasgow Outcome Score of 1 (good outcome - mild or no disability) at 90 days
  • No significant differences in primary outcome: 66% hypothermia vs 63% normothermia (OR 1.14, 95% CI 0.88-1.48, p=0.32)
  • No significant differences in death rates at follow-up (6% both groups), ICU stay (mean 6 days both groups), total hospitalization (mean 16 days both groups)
  • Postoperative bacteremia significantly higher in hypothermia group (5% vs 3%, p=0.05)
  • No significant differences in rates of neurologic deficits, cardiovascular events, or coagulation problems
  • Target temperatures achieved: 50% of hypothermia patients reached 34.5°C or lower within 1 hour before clipping
  • Subgroup analysis showed possible benefit in males and patients with surgery 8-14 days after SAH, but these differences disappeared after adjustment for covariates
  • Two planned interim analyses performed after 357 and 655 patients
  • Nearly perfect follow-up rate (99.9%)

Design

Study Type: Prospective randomized controlled trial, partially blinded

Randomization: 1

Blinding: All study personnel except anesthesiologists involved in intraoperative care were unaware of treatment assignments. Outcome assessors (neurologic examiners and neuropsychologists) were blinded to treatment assignment.

Enrollment Period: February 2000 to April 2003

Follow-up Duration: Approximately 90 days after surgery (median 88 days; 10th and 90th percentiles 72 and 113 days)

Centers: 30

Countries: United States, Canada, United Kingdom, New Zealand, Australia, Austria, Germany

Sample Size: 1001

Analysis: Intention-to-treat analysis. Cochran-Mantel-Haenszel statistic used to compare rates of good outcomes with stratification by study site and time from SAH to surgery. T-tests or Wilcoxon rank-sum test for interval variables. Fisher's exact test for 2x2 tables. Freeman-Halton extension to Fisher's exact test for categorical variables with more than 2 outcomes. Subgroup analyses using method of Grizzle et al. Lan and DeMets interim monitoring method with O'Brien-Fleming spending function. Two-sided P values not adjusted for interim analyses.


Inclusion Criteria

  • Age at least 18 years
  • Not pregnant
  • Subarachnoid hemorrhage from radiologically demonstrated intracranial aneurysm within 14 days before surgery
  • World Federation of Neurological Surgeons (WFNS) score of I, II, or III (good-grade) at enrollment, verified on arrival in operating room
  • Rankin score of 0 (no neurologic disability) or 1 (mild disability) before hemorrhage
  • Patient or legal representative provided informed consent

Exclusion Criteria

  • Body mass index greater than 35
  • Cold-related disorder
  • Endotracheal tube already in place
  • Traumatic subarachnoid hemorrhage
  • Presentation more than 14 days after hemorrhage
  • Age less than 18 years

Baseline Characteristics

CharacteristicControlActive
Total patients501499
Mean age (years)51 ± 1352 ± 12
Female66%65%
Race - White80%80%
Race - Black8%6%
Race - Hispanic6%5%
Race - Other6%9%
Current smoker54%54%
WFNS Score I (GCS 15, no motor deficit)66%67%
WFNS Score II (GCS 13-14, no motor deficit)30%28%
WFNS Score III (GCS 13-14, motor deficit)5%5%
Fisher Grade I (no SAH blood)5%6%
Fisher Grade II (diffuse blood)34%35%
Fisher Grade III (localized clot)48%47%
Fisher Grade IV (intraparenchymal or ventricular clot)14%12%
Hydrocephalus on first CT41%38%
Mean time SAH to surgery (days)3 ± 33 ± 3
Median time SAH to surgery (days)22
Nimodipine treatment500 of 501 patients498 of 499 patients
Preoperative fever (≥38.5°C)5%

Arms

FieldControlIntraoperative Hypothermia
InterventionTarget esophageal temperature maintained between 36°C and 37°C (target 36.5°C) during surgery. Anesthesia induced with thiopental or etomidate and maintained with isoflurane or desflurane, fentanyl or remifentanil, and oxygen/nitrous oxide or oxygen/air mix. Temperature monitored in retrocardiac esophagus. Patient covered with forced-air blanket connected to heating-cooling unit. Optional use of circulating water mattress. Thiopental or etomidate permitted for cerebral protection during temporary vessel occlusion. Nimodipine started before or after surgery in all but one patient. Standardized pre- and postoperative care for SAH patients.Target esophageal temperature between 32.5°C and 33.5°C (target 33°C) by time of first clip placement. Surface cooling using forced-air blanket connected to heating-cooling unit (PolarAir). Optional use of circulating water mattress and intravenous cold saline. Cooling initiated after endotracheal intubation and positioning, reduced as quickly as possible without delaying surgery. Rewarming began after last aneurysm clip secured. Anesthesia protocol identical to normothermia group: induced with thiopental or etomidate, maintained with isoflurane or desflurane, fentanyl or remifentanil, and oxygen/nitrous oxide or oxygen/air mix. Temperature monitored in retrocardiac esophagus. Thiopental or etomidate permitted for cerebral protection during temporary vessel occlusion. Nimodipine started before or after surgery in all but one patient. Standardized pre- and postoperative care for SAH patients.
DurationIntraoperative period only, with follow-up to approximately 90 daysIntraoperative period only (cooling stopped after final clip placed), with follow-up to approximately 90 days

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Good outcome defined as Glasgow Outcome Score of 1 (minor or no disability) at approximately 90 days after surgeryPrimary314 of 501 patients (63%)329 of 499 patients (66%)0.32
Glasgow Outcome Score 2 (moderate disability) at 90 daysSecondary108 of 501 (22%)105 of 499 (21%)
Glasgow Outcome Score 3 (severe disability) at 90 daysSecondary47 of 501 (9%)35 of 499 (7%)
Glasgow Outcome Score 4 (vegetative state) at 90 daysSecondary0 of 5011 of 499 (<1%)
Glasgow Outcome Score 5 (death) at 90 daysSecondary32 of 501 (6%)29 of 499 (6%)
Rankin score 0 or 1 (mild or no neurologic disability) at 90 daysSecondary318 of 501 (63%)333 of 499 (67%)OR 1.14, 95% CI 0.88-1.490.32
Barthel index 95-100 (independent in activities of daily living) at 90 daysSecondary403 of 468 surviving patients (86%)416 of 469 surviving patients (89%)OR 1.27, 95% CI 0.86-1.870.23
NIH Stroke Scale score 0 (no deficit) at 90 daysSecondary291 of 452 patients (64%)306 of 461 patients (66%)OR 1.08, 95% CI 0.82-1.420.60
Mean ICU length of stay (days)Secondary6 ± 56 ± 5
Mean total hospital length of stay (days)Secondary16 ± 1116 ± 9
Discharged directly to home (among survivors)Secondary59%61%
In-hospital deathSecondary23 patients24 patients0.88
NIH Stroke Scale increase of ≥4 points at 3-6 hours post-surgerySecondary42% (excluding intubated/sedated)39% (excluding intubated/sedated)
NIH Stroke Scale increase of ≥4 points at 24 hours post-surgerySecondary28% (excluding intubated/sedated)27% (excluding intubated/sedated)
Intubated 2 hours after surgerySecondary13%25%
Intubated 24 hours after surgerySecondary10%10%
Temperature at placement of first clip (°C)Secondary36.7 ± 0.533.3 ± 0.80.001
Temperature 2 hours after surgery (°C)Secondary37.1 ± 0.736.4 ± 1.00.001
Crystalloid administration (ml)Secondary3287 ± 15503828 ± 15950.001
Urinary output (ml)Secondary1679 ± 10592052 ± 12590.001
BacteremiaAdverse13 patients (3%)25 patients (5%)0.05
Intraparenchymal hemorrhageAdverse4%3%0.17
Epidural or subdural hemorrhageAdverse5%5%0.89
Delayed ischemic neurologic deficitAdverse22%23%0.82
Cerebral infarctionAdverse30%26%0.23
Brain swellingAdverse26%24%0.56
SeizureAdverse6%7%0.61
Myocardial ischemia or infarctionAdverse1%2%0.30
Congestive heart failure or pulmonary edemaAdverse12%10%0.42
Ventricular fibrillation or tachycardiaAdverse1%1%0.34
Supraventricular dysrhythmiaAdverse5%4%0.43
Severe hemorrhage (≥1000 ml in 24 hr)Adverse6%7%0.37
Red-cell transfusion at any timeAdverse31%34%0.25
CoagulopathyAdverse1%1%0.22
Incision or bone-flap infectionAdverse2%2%0.81
Meningitis or ventriculitisAdverse4%6%0.31
PneumoniaAdverse7%7%0.90
Urinary tract infectionAdverse18%15%0.31
Preoperative fever (≥38.5°C)Adverse2%5%0.005

Subgroup Analysis

Subgroup analyses showed a significant interaction between time to surgery and treatment (p=0.04). In patients with surgery 0-7 days after SAH (n=907), good outcomes were 64% hypothermia vs 63% normothermia (OR 1.06, 95% CI 0.81-1.40). In patients with surgery 8-14 days after SAH (n=93), good outcomes were 83% hypothermia vs 61% normothermia (OR 2.70, 95% CI 1.00-7.30), but this difference was no longer significant after adjusting for baseline factors. Interaction between sex and treatment was also significant (p=0.03). Among men, 69% hypothermia vs 57% normothermia had good outcomes (OR 1.78, 95% CI 1.12-2.84), but this disappeared after adjustment for covariates, particularly age. Among women, 64.3% hypothermia vs 65.8% normothermia had good outcomes (not significant). Age >50 years, WFNS score >II, Fisher grade >II, severe intraoperative hemorrhage, and temporary clip placement ≥20 minutes were associated with worse outcomes without temperature-related interactions.


Criticisms

  • Patients cooled to only 33°C and only for intraoperative period - colder temperatures or longer cooling periods might yield different results
  • Relatively slow rate of cooling may have resulted in inadequate protection during early stage of retractor placement or aneurysm exposure (though 50% achieved 34.5°C or lower within 1 hour before clipping)
  • Esophageal rather than brain temperature controlled - potential discrepancies between measurements
  • No control of postoperative care aspects
  • Relatively crude outcome assessment (Glasgow Outcome Scale), though no differences found with other outcome measures either
  • Study restricted to good-grade patients (WFNS I-III), limiting generalizability to poor-grade patients
  • Obese patients (BMI >35) excluded, limiting applicability to this population
  • Single-center pilot study findings may not generalize across all centers
  • Subgroup findings (benefit in males and 8-14 day surgery group) were secondary analyses and must be interpreted cautiously
  • Delayed surgery subgroup was small (93 patients) and imbalanced in baseline characteristics
  • Neuropsychological examination results still being evaluated at time of publication
  • Inability to completely blind outcome assessors to treatment (though they were independent of treatment teams)
  • Two centers dropped during trial due to protocol compliance issues

Funding

Supported by grant from National Institute of Neurological Disease and Stroke (RO1 NS38554)

Based on: IHAST (New England Journal of Medicine, 2005)

Authors: Michael M. Todd, Bradley J. Hindman, William R. Clarke, ..., for the Intraoperative Hypothermia for Aneurysm Surgery Trial (IHAST) Investigators

Citation: N Engl J Med 2005;352:135-45

Content summarized and formatted by NeuroTrials.ai.